Onsenal
celecoxib
Table of contents
Overview
The marketing authorisation for Onsenal has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Onsenal
|
| Agency product number |
EMEA/H/C/000466
|
| Active substance |
Celecoxib
|
| International non-proprietary name (INN) or common name |
celecoxib
|
| Therapeutic area (MeSH) |
Adenomatous Polyposis Coli
|
| Anatomical therapeutic chemical (ATC) code |
L01XX33
|
Exceptional circumstances |
This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see Pre-authorisation guidance. |
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Pfizer Limited
|
| Revision |
13
|
| Date of issue of marketing authorisation valid throughout the European Union |
17/10/2003
|
| Contact address | |
Product information
28/03/2011 Onsenal - EMEA/H/C/000466 - II/0028
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Therapeutic indication
Onsenal is indicated for the reduction of the number of adenomatous intestinal polyps in familial adenomatous polyposis (FAP), as an adjunct to surgery and further endoscopic surveillance (see section 4.4).
The effect of Onsenal-induced reduction of polyp burden on the risk of intestinal cancer has not been demonstrated (see sections 4.4 and 5.1)